AIDS-associated Kaposi sarcoma: Outcomes after initiation of antiretroviral therapy at a university-affiliated hospital in urban Zimbabwe

International Journal of Infectious Diseases

Volumn 17, Issue 10, 2013, Pages

  Nelson, Bradley C ^a,b   Borok, Margaret Z ^c   Mhlanga, Tafadzwa O ^c   Makadzange, Azure T ^c,d   Campbell, Thomas B ^b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO HEALTH SYSTEM   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

AIDS; Antiretroviral therapy; HIV; Kaposi sarcoma

Indexed keywords

EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE;

AIDS ASSOCIATED KAPOSI SARCOMA; AIDS PATIENT; ANTIRETROVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; MALE; MEDICAL RECORD; PHARMACEUTICAL CARE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; WEIGHT GAIN; ZIMBABWE;

AIDS; ANTIRETROVIRAL THERAPY; HIV; KAPOSI SARCOMA;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; COINFECTION; DRUG THERAPY, COMBINATION; FEMALE; HERPESVIRUS 8, HUMAN; HIV-1; HOSPITALS, UNIVERSITY; HUMANS; KAPLAN-MEIER ESTIMATE; LAMIVUDINE; MALE; MULTIVARIATE ANALYSIS; NEVIRAPINE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SARCOMA, KAPOSI; STAVUDINE; TREATMENT OUTCOME; URBAN POPULATION; ZIMBABWE;

EID: 84883747942     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2013.04.011     Document Type: Article

References (26)

1. Vanni T., Sprinz E., Machado M.W., Santana Rde C., Fonseca B.A., Schwartsmann G. Systemic treatment of AIDS-related Kaposi sarcoma: current status and perspectives. Cancer Treat Rev 2006, 32:445-455.
2. Hengge U.R., Ruzicka T., Tyring S.K., Stuschke M., Roggendorf M., Schwartz R.A., Seeber S. Update on Kaposi's sarcoma and other HHV-8 associated diseases. Part 1: epidemiology, environmental predispositions, clinical manifestations, and therapy. Lancet Infect Dis 2002, 2:281-292.
3. Dal Maso L., Franceschi S. Epidemiology of AIDS-related tumours in developed and developing countries. Eur J Cancer 2001, 37:1188-1201.
4. Orem J., Otieno M.W., Remick S.C. AIDS-associated cancer in developing nations. Curr Opin Oncol 2004, 16:468-476.
5. Baeten J.M., Chohan B.H., Lavreys L., Rakwar J.P., Ashley R., Richardson B.A., et al. Correlates of human herpesvirus 8 seropositivity among heterosexual men in Kenya. AIDS 2002, 16:2073-2078.
6. Eltom M.A., Mbulaiteye S.M., Dada A.J., Whitby D., Biggar R.J. Transmission of human herpesvirus 8 by sexual activity among adults in Lagos, Nigeria. AIDS 2002, 16:2473-2478.
7. Lavreys L., Chohan B., Ashley R., Richardson B.A., Corey L., Mandaliya K., et al. Human herpesvirus 8: seroprevalence and correlates in prostitutes in Mombasa, Kenya. J Infect Dis 2003, 187:359-363.
8. Klaskala W., Brayfield B.P., Kankasa C., Bhat G., West J.T., Mitchell C.D., Wood C. Epidemiological characteristics of human herpesvirus-8 infection in a large population of antenatal women in Zambia. J Med Virol 2007, 75:93-100.
9. Olsen S.J., Chang Y., Moore P.S., Biggar R.J., Melbye M. Increasing Kaposi's sarcoma-associated herpesvirus seroprevalence with age in a highly Kaposi's sarcoma endemic region, Zambia in 1985. AIDS 1998, 12:1921-1925.
10. Newton R., Ziegler J., Bourboulia D., Casabonne D., Beral V., Mbidde E., et al. The seroepidemiology of Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in adults with cancer in Uganda. Int J Cancer 2003, 103:226-232.
11. Engels E.A., Pfeiffer R.M., Goedert J.J., Virgo P., McNeel T.S., Scoppa S.M., Biggar R.J. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006, 20:1645-1654.
12. Cattelan A.M., Calabrò M.L., De Rossi A., Aversa S.M., Barbierato M., Trevenzoli M., et al. Long-term clinical outcome of AIDS-related Kaposi's sarcoma during highly active antiretroviral therapy. Int J Oncol 2005, 27:779-785.
13. Cattelan A.M., Calabrò M.L., Gasperini P., Aversa S.M., Zanchetta M., Meneghetti F., et al. Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome. J Natl Cancer Inst Monogr 2000, 28:44-49.
14. Paparizos V.A., Kyriakis K.P., Papastamopoulos V., Hadjivassiliou M., Stavrianeas N.G. Response of AIDS-associated Kaposi sarcoma to highly active antiretroviral therapy alone. J Acquir Immune Defic Syndr 2002, 30:257-258.
15. Bower M., Weir J., Francis N., Newsom-Davis T., Powles S., Crook T., et al. The effect of HAART in 254 consecutive patients with AIDS-related Kaposi's sarcoma. AIDS 2009, 23:1701-1706.
16. Lawn S.D., Harries A.D., Anglaret X., Myer L., Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008, 22:1897-1908.
17. Zachariah R., Fitzgerald M., Massaquoi M., Pasulani O., Arnould L., Makombe S., Harries A.D. Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS 2006, 20:2355-2360.
18. Castelnuovo B., Manabe Y.C., Kiragga A., Kamya M., Easterbrook P., Kambugu A. Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort. Clin Infect Dis 2009, 49:965-972.
19. Borok M., Fiorillo S., Gudza I., Putnam B., Ndemera B., White I.E., et al. Evaluation of plasma human herpesvirus 8 DNA as a marker of clinical outcomes during antiretroviral therapy for AIDS-related Kaposi sarcoma in Zimbabwe. Clin Infect Dis 2010, 51:342-349.
20. Makombe S.D., Harries A.D., Yu J.K., Hochgesang M., Mhango E., Weigel R., et al. Outcomes of patients with Kaposi's sarcoma who start antiretroviral therapy under routine programme conditions in Malawi. Trop Doct 2008, 38:5-7.
21. Nasti G., Talamini R., Antinori A., Martellotta F., Jacchetti G., Chiodo F., et al. AIDS-related Kaposi's sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group on AIDS and Tumors and the Italian Cohort of Patients Naïve from Antiretrovirals. J Clin Oncol 2003, 21:2876-2882.
22. Krown S.E., Testa M.A., Huang J. AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 1997, 15:3085-3092.
23. Chokunonga E., Levy L.M., Bassett M.T., Borok M.Z., Mauchaza B.G., Chirenje M.Z., Parkin D.M. AIDS and cancer in Africa: the evolving epidemic in Zimbabwe. AIDS 1999, 13:2583-2588.
24. Gondos A., Chokunonga E., Brenner H., Parkin D.M., Sankila R., Borok M.Z., et al. Cancer survival in a southern African urban population. Int J Cancer 2004, 112:860-864.
25. Brinkhof M.W., Pujades-Rodriguez M., Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One 2009, 4:e5790.
26. Bassett I.V., Wang B., Chetty S., Mazibuko M., Bearnot B., Giddy J., et al. Loss to care and death before antiretroviral therapy in Durban, South Africa. J Acquir Immune Defic Syndr 2009, 51:135-139.